OP
VRTX icon

ORG Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

ORG Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$87.5K Sell
193
-53
-22% -$22.8K 0.02% 482
2025
Q3 		$96.3K Sell
246
-4
-2% -$1.67K 0.02% 469
2025
Q2 		$113K Buy
250
+37
+17% +$17.1K 0.02% 410
2025
Q1 		$103K Buy
213
+111
+109% +$51.7K 0.03% 380
2024
Q4 		$41.1K Buy
102
+53
+108% +$24.6K 0.01% 603
2024
Q3 		$22.8K Sell
49
-3
-6% -$1.44K ﹤0.01% 652
2024
Q2 		$24.5K Buy
52
+44
+550% +$19.1K ﹤0.01% 1011
2024
Q1 		$3.36K Sell
8
-7
-47% -$2.96K 0.01% 372
2023
Q4 		$6.1K Sell
15
-42
-74% -$15.5K ﹤0.01% 819
2023
Q3 		$19.8K Sell
57
-4
-7% -$1.4K 0.01% 698
2023
Q2 		$21.3K Buy
+61
New +$20.6K ﹤0.01% 859

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ORG Partners's VRTX Position: Q4 2025 in Review

ORG Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 22% in Q4 2025, selling an estimated $22.8K and leaving 193 shares worth $87.5K. The position accounts for 0.02% of the portfolio, ranked #482.

ORG Partners first reported a position in VRTX in Q2 2023 and has held it in 11 quarters since. The position peaked at $113K in Q2 2025. 1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • ORG Partners held 193 shares of Vertex Pharmaceuticals worth $87.5K as of Q4 2025.
  • ORG Partners sold 53 Vertex Pharmaceuticals shares in Q4 2025, an estimated $22.8K.
  • Vertex Pharmaceuticals made up 0.02% of ORG Partners's portfolio in Q4 2025, its #482 holding.
  • ORG Partners first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 11 quarters since.
  • ORG Partners's Vertex Pharmaceuticals position peaked at $113K in Q2 2025.
  • 1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.